The management of paratesticular rhabdomyosarcoma.
Between 1974 and 1986 15 patients presented to the Royal Marsden Hospital with paratesticular rhabdomysarcoma. Of 10 patients presenting with Stage I disease, eight were treated with adjuvant chemotherapy. Six (75%) remain continuously disease-free 1.2-8.3 years from presentation. The two who relapsed have been salvaged with further treatment and remain disease-free 7.5 years and 10.3 years from original presentation. Three patients presented with regional node involvement and two are disease-free 3.3 and 3.7 years from presentation; the other died from disease. Two patients presented with Stage III disease and one remains alive and disease-free at 7.8 years from presentation. The efficacy of chemotherapy has diminished the roles of surgery and radiotherapy following radical excision in Stage I disease. However, aggressive multi-modality approaches are relevant for metastatic disease.
Hamilton
C R
CR
Testicular Tumour Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Pinkerton
R
R
Horwich
A
A
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005834:Genital Neoplasms, Male / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008297:Male; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D012611:Scrotum / Q000601:surgery